Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ophthalmic panel tackles Prelex technique

This article was originally published in The Gray Sheet

Executive Summary

Study criteria for intraocular lenses to correct presbyopia following clear lens extraction will be explored March 5 by FDA's Ophthalmic Devices Panel in Gaithersburg, Md. Potential candidates for a presbyopic lens exchange (Prelex) indication include Advanced Medical Optics' Array multifocal lens, Eyeonics' CrystaLens AT-45 and Alcon's Acrysof multifocal IOL. Array has been available for U.S. use in cataract surgery since 1997, while AT-45 earned approval Nov. 14 for aphakic treatment of near, immediate and distance vision (1"The Gray Sheet" Dec. 22, 2003, p. 25)...

You may also be interested in...

CrystaLens Accommodating IOL First To Market; Firm Eyes Expanded Labeling

Eyeonics, Inc. will file a supplemental PMA for its CrystaLens AT-45 accommodating posterior chamber intraocular lens to broaden the treatment range beyond 1.0 diopter

Atlas Biomed Unlocking Japan’s OTC Market With Direct-To-Consumer DNA And Microbiome Tests

Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus. 

Hair Supplement Linked To Cases Of Severe Hepatitis In France

France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts